Bio-Techne Corp at Barclays Global Healthcare Conference Transcript
All right. Good afternoon, everybody. I'm Luke Sergott. I cover life sciences tools and diagnostics here at Barclays. It's my pleasure to have with me Jim Hippel from CFO of Bio-Techne. It's been a long time. We're just commenting it's about 3 years for you. I'm glad to have you back.
Questions & Answers
To kick it off, let's start off just like real high-level thoughts of what you saw coming out of your quarter. The underlying market demand going into your guidance and -- we can start there and then dig in further.
Sure. I think I'll start on a positive note, which is that our underlying demand and the health of our end markets, we believe, are still very strong. And despite this print, what makes me say that is in the last few years of COVID noise, you got to dig a little
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
